-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 5 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Postrecurrence treatment in neo/adjuvant trials. - 5 month(s) ago
Is it better to treat all patients early on, or to spare those who are already cured and only treat those who relapse?
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Great article by @Timothee_MD On his @JAMAOnc Paper out today. https://t.co/X6ah7fKpr8
-
-
Mashup Score: 72My 2 hour lecture at ASCO on Critical Appraisal - 5 month(s) ago
My thank you to supporters
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
This 2 hour lecture available here https://t.co/jZ1sjO0WB6 https://t.co/Im2nSMPBEO
-
-
Mashup Score: 69My 2 hour lecture at ASCO on Critical Appraisal - 5 month(s) ago
My thank you to supporters
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
This 2 hour lecture available here https://t.co/jZ1sjO0WB6 https://t.co/Im2nSMPBEO
-
-
Mashup Score: 28EDITOR'S PICK: Overdiagnosis and Overtreatment in Melanoma. - 5 month(s) ago
A paper advocating against routine skin screening “for all”.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Overdiagnosis and overtreatment in melanoma https://t.co/4TCSMIKwRd via @Timothee_MD & @VPrasadMDMPH @AdeAdamson
-
-
Mashup Score: 35Special post-ASCO 2024 edition ! - 6 month(s) ago
Timothee Olivier and I discuss the top ASCO 2024 abstracts!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
By popular demand, @Timothee_MD and I review #ASCO24 #asco2024 highlights in this video Subscribe to the Drug Development Letter for Free Updates on.... well.. drug development https://t.co/OfyNZ3Cyq5 https://t.co/Hgq8OxcELv
-
-
Mashup Score: 35Special post-ASCO 2024 edition ! - 6 month(s) ago
Timothee Olivier and I discuss the top ASCO 2024 abstracts!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
By popular demand, @Timothee_MD and I review #ASCO24 #asco2024 highlights in this video Subscribe to the Drug Development Letter for Free Updates on.... well.. drug development https://t.co/OfyNZ3Cyq5 https://t.co/Hgq8OxcELv
-
-
Mashup Score: 11Imatinib is still better first than asiminib. Don't be fooled. - 6 month(s) ago
Limitations in the ASC4FIRST trial : Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Just out @Timothee_MD and I ask if imatinib has been dethroned #asco24 #asco2024 https://t.co/mezDS9B8nO
-
-
Mashup Score: 2ASCO pre-game show - 6 month(s) ago
Timothee Olivier and I discuss what you should be looking for at ASCO24
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @Timothee_MD: Such level of spin in the published conclusion!! @JCO_ASCO ❗️ We predicted it👇 https://t.co/LZJjfz9L64 https://t.co/Movx…
-
-
Mashup Score: 18
Long term PFS results are presented at ASCO 2024, but the trial had a suboptimal control arm.
Source: www.drugdevletter.comCategories: General Medicine News, Expert PicksTweet-
How the hell did Crown run with an inferior control arm? Alectinib beat Crizo in 2017. @Timothee_MD https://t.co/I1SkFKB9A9 #ASCO24
-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…